Lingxian Zhang Selected Research

RGB 286638

1/2021

CDK inhibitors in cancer therapy, an overview of recent development.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Lingxian Zhang Research Topics

Disease

2	Breast Neoplasms (Breast Cancer) 04/2022 - 01/2021
2	Neoplasms (Cancer) 04/2022 - 01/2021

Drug/Important Bio-Agent (IBA)

1	rebastinibIBA 04/2022
1	Oncogene Proteins (Oncogene Protein)IBA 04/2022
1	RGB 286638IBA 01/2021
1	dinaciclibIBA 01/2021
1	14- methyl- 20- oxa- 5,7,14,26- tetraazatetracyclo(19.3.1.1(2,6).1(8,12))heptacosa- 1(25),2(26),3,5,8(27),9,11,16,21,23- decaeneIBA 01/2021
1	roniciclibIBA 01/2021
1	RoscovitineIBA 01/2021
1	AntibodiesIBA 01/2021
1	P276-00IBA 01/2021
1	EnzymesIBA 01/2021
1	Hormones (Hormone)IBA 01/2021
1	alvocidib (flavopiridol)IBA 01/2021
1	4- (2,6- dichlorobenzoylamino)- 1H- pyrazole- 3- carboxylic acid piperidin-4-ylamideIBA 01/2021

Therapy/Procedure

1	Therapeutics 01/2021